Cancer Guidelines Database

Access quality cancer guidelines from a single Canadian source

We've listed guidelines under your selection of "Location". The most recent guidelines are first.

Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline

Year: 2019
AGREE II score: Available
Developer organization: American Society of Clinical Oncology
This is a clinical practice guideline for patients with multiple myeloma. The guideline provides recommendations for the treatment of both newly diagnosed and relapsed patients. Outcomes of interest include overall survival, progression-free survival, response rate, and quality of life.

Preoperative or Postoperative Therapy for the Management of Patients With Stage II or III Rectal Cancer

Year: 2019
AGREE II score: Available
Developer organization: Cancer Care Ontario
This is a clinical practice guideline for adult patients with clinically resectable or resected stage II or III rectal cancer. The guideline examines the appropriate preoperative staging tests and the role of postoperative radiotherapy (RT) and/or chemotherapy (CT) for patients with resected stage II or III rectal cancer. The primary outcomes of interest are increase in overall survival and delaying local recurrence.

Evidence Based Recommendations for the Assessment and Management of Radiation-Induced Skin Toxicities in Breast Cancer: Part 3. Skin Health Promotion: Health Promotion Interventions

Year: 2018
AGREE II score: Available
Developer organization: Cancer Care Manitoba
This clinical practice guideline if part of a series of guidelines for adults with breast cancer who are experiencing radiation-induced skin toxicities. The guideline provides recommendations regarding interventions aimed at the promotion of skin health. Specific topics discussed include the promotion of skin hygiene, promotion of comfort, preventing infections, protection from trauma, and protection from the environment.

Evidence Based Recommendations for the Assessment and Management of Radiation-Induced Skin Toxicities in Breast Cancer: Part 4. Management of Acute Radiation-Induced Skin Toxicities

Year: 2018
AGREE II score: Available
Developer organization: Cancer Care Manitoba
This clinical practice guideline if part of a series of guidelines for adults with breast cancer who are experiencing radiation-induced skin toxicities. The guideline focuses on the clinical assessment and management of these patients. Outcomes of interest include improved care delivery and quality of life, enhanced treatment compliance, as well as minimized patient burden regarding dressings (i.e. cost, frequency/difficulty of dressing changes).

Evidence Based Recommendations for the Assessment and Management of Radiation-Induced Skin Toxicities in Breast Cancer: Part 5. Management of Long-Term Effects

Year: 2018
AGREE II score: Available
Developer organization: Cancer Care Manitoba
This clinical practice guideline if part of a series of guidelines for adults with breast cancer who are experiencing radiation-induced skin toxicities. The guideline focuses on the management of long term effects, and provides recommendations on 1 month post-treatment and late reactions to promote cleanliness, treat the wound, prevent infections, protect from trauma and the environment, promote skin health and maintain skin flexibility.

Biodegradable Rectal Spacers for Prostate Cancer Radiotherapy

Year: 2019
AGREE II score: Available
Developer organization: Cancer Care Ontario
This is a clinical practice guideline for patients undergoing radiation treatment for localized prostate cancer. The guideline examines the use of biodegradable spacers for prostate cancer treatment. A topic of interest is biodegradable spacer insertion as a technology that may be used to decrease toxicity and maintain quality of life (QOL) in appropriately selected patients.

Referral of Suspected Lung Cancer by Family Physicians and Other Primary Care Providers

Year: 2019
AGREE II score: Available
Developer organization: Cancer Care Ontario
This is a clinical practice guideline for patients presenting to primary care services with signs and/or symptoms of lung cancer. The guideline examines the referral process for this patient population. Topics of interest include factors that have been shown to increase the risk of lung cancer, symptoms that should be present in a person before referral, indications for chest computed tomography (CT) scan, and follow-up to diagnostic investigations.

Provincial Esophageal Cancer and Gastro-Esophageal Junction Cancer Treatment Guidelines

Year: 2018
AGREE II score: Unavailable
Developer organization: Saskatchewan Cancer Agency
This is a clinical practice guideline for adult patients with esophageal cancer or cancer of the gastro-esophageal junction. The guideline provides recommendations on assessment, systemic therapy, surgical approaches, and post-curative therapy follow-up of these patients. The discussion of treatment is stratified by stage, performance status, and disease type. Chemotherapy regimens are also considered.

Recommendations on Screening for Breast Cancer in Women Aged 40–74 Years Who are not at Increased Risk for Breast Cancer

Year: 2018
AGREE II score: Available
Developer organization: Canadian Task Force on Preventive Health Care
This is a clinical practice guideline for women aged 40-74 who are not at an increased risk for developing breast cancer. The guideline discusses breast cancer screening in this population, and provides specific recommendations on appropriate screening modalities. Recommendations for screening are based on age.

Gallium-68 PET Imaging in Neuroendocrine Tumours

Year: 2018
AGREE II score: Available
Developer organization: Cancer Care Ontario
This is a clinical practice guideline for adult and pediatric patients with suspected or diagnosed well-differentiated neuroendocrine tumours (NETs). The guideline discusses the clinical utility of Gallium-68 positron emission tomography (PET) compared with PET / computed tomography imaging for the initial diagnosis, staging, re-staging, response evaluation, and routine surveillance of patients with NETs.